Last reviewed · How we verify

Kanecia Obie Zimmerman — Portfolio Competitive Intelligence Brief

Kanecia Obie Zimmerman pipeline: 2 marketed, 0 filed, 0 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
0.25% Timolol Maleate Gel Forming Solution 0.25% Timolol Maleate Gel Forming Solution marketed
0.5% Timolol Maleate Gel Forming Solution 0.5% Timolol Maleate Gel Forming Solution marketed

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Kanecia Obie Zimmerman:

Cite this brief

Drug Landscape (2026). Kanecia Obie Zimmerman — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kanecia-obie-zimmerman. Accessed 2026-05-16.

Related